NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SLS

SELLAS Life Sciences Group Inc

Apr 23 • 04:00PM ET

1.31

Dollar change +0.02
Percentage change 1.55	%

Healthcare • Biotechnology • USA • NASD

Peers: TGTX KPTI IMMP AFMD ADAP BCRX ACET AVDL TLSA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.54	Insider Own	2.08%	Shs Outstand	90.85M	Perf Week	1.55%
Market Cap	119.01M	Forward P/E	-	EPS next Y	-0.47	Insider Trans	0.00%	Shs Float	88.96M	Perf Month	6.50%
Income	-30.88M	PEG	-	EPS next Q	-0.10	Inst Own	6.84%	Short Float	9.19%	Perf Quarter	14.91%
Sales	0.00M	P/S	-	EPS this Y	15.00%	Inst Trans	14.98%	Short Ratio	4.06	Perf Half Y	3.97%
Book/sh	0.13	P/B	10.24	EPS next Y	-9.41%	ROA	-237.23%	Short Interest	8.18M	Perf Year	-14.94%
Cash/sh	0.15	P/C	8.51	EPS next 5Y	42.51%	ROE	-4147.88%	52W Range	0.77 - 1.84	Perf YTD	25.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	45.94%	ROI	-311.24%	52W High	-28.80%	Beta	2.29
Dividend TTM	-	Quick Ratio	1.72	Sales past 5Y	22.63%	Gross Margin	-	52W Low	69.69%	ATR (14)	0.09
Dividend Ex-Date	Mar 24, 2011	Current Ratio	1.72	EPS Y/Y TTM	60.51%	Oper. Margin	-	RSI (14)	65.20	Volatility	6.83% 7.40%
Employees	15	Debt/Eq	0.11	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	5.83
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	64.03%	Payout	-	Rel Volume	0.69	Prev Close	1.29
Sales Surprise	-	EPS Surprise	43.77%	Sales Q/Q	-	Earnings	Mar 20 AMC	Avg Volume	2.01M	Price	1.31
SMA20	12.93%	SMA50	10.46%	SMA200	10.78%	Trades		Volume	1,687,165	Change	1.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-21-21	Initiated	Cantor Fitzgerald	Overweight	$18
Nov-01-18	Initiated	Oppenheimer	Outperform
Apr-02-18	Initiated	H.C. Wainwright	Buy	$11
Mar-19-18	Upgrade	Maxim Group	Hold → Buy	$13

Apr-23-25 10:23AM	SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-08-25 08:45AM	SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML (GlobeNewswire)
Apr-05-25 12:37PM	Undercovered Dozen: Power Metals, Verses AI, TFS Financial, Nextdoor + (Seeking Alpha)
Mar-31-25 03:03PM	Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (Seeking Alpha)
Mar-20-25 04:05PM	SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
10:10AM	Loading…
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-21-25 07:29AM	Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment (Clinical Trials Arena)
Feb-20-25 08:45AM	SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL (GlobeNewswire)
Jan-28-25 03:11PM	SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -17.02%
Jan-23-25 08:10AM	SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia (GlobeNewswire) -13.25%
Jan-08-25 08:20AM	SELLAS Announces Key Business Objectives for 2025 (GlobeNewswire) -9.49%
Jan-02-25 08:00AM	SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET (GlobeNewswire)
Dec-10-24 08:30AM	SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia (GlobeNewswire)
Dec-09-24 08:45AM	SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML (GlobeNewswire)
Nov-28-24 05:37AM	SELLAS announces data indicating key predictor of response to SLS009 in solid cancers (Clinical Trials Arena)
08:45AM	Loading…
Nov-27-24 08:45AM	SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers (GlobeNewswire)
Nov-13-24 04:15PM	SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.93%
Nov-05-24 09:55AM	SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 (GlobeNewswire)
Oct-15-24 08:45AM	SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia (GlobeNewswire)
Oct-10-24 04:05PM	SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-18-24 03:09PM	Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory (Insider Monkey)
Aug-13-24 04:10PM	SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-24 08:45AM	SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas (GlobeNewswire)
Jul-31-24 08:30AM	SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market (GlobeNewswire) -7.20%
Jul-16-24 09:05AM	SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia (GlobeNewswire)
Jul-08-24 08:45AM	SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia (GlobeNewswire)
Jun-24-24 09:05AM	SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia (GlobeNewswire)
Jun-17-24 09:45AM	Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase (GlobeNewswire) -16.67%
09:05AM	SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia (GlobeNewswire)
Jun-10-24 08:40AM	SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML (GlobeNewswire)
10:54PM	Loading…
May-14-24 10:54PM	SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024 (InvestorPlace) +7.30%
04:05PM	SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-24 08:35AM	SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level (GlobeNewswire)
Apr-29-24 08:45AM	SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study (GlobeNewswire) -17.12%
Mar-28-24 10:54PM	SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023 (InvestorPlace) +5.94%
04:05PM	SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib) Treating Diffuse Large B Cell Lymphoma (PR Newswire)
Mar-26-24 07:35AM	SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study (GlobeNewswire)
Mar-19-24 04:05PM	SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:47AM	SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET (GlobeNewswire)
Mar-15-24 09:00AM	SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -29.03%
Mar-08-24 08:00AM	SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships (GlobeNewswire)
Mar-01-24 08:30AM	SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference (GlobeNewswire)
Feb-29-24 08:00AM	SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time (GlobeNewswire)
Feb-06-24 08:30AM	SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget (GlobeNewswire) +12.24%
Jan-25-24 08:45AM	SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference (GlobeNewswire)
Jan-11-24 06:00AM	GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia (PR Newswire)
Jan-10-24 11:30AM	SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate (Zacks)
Jan-09-24 08:30AM	SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients (GlobeNewswire)
Jan-04-24 09:01AM	SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering (GlobeNewswire) -35.77%
08:41AM	Why Is Sellas Life Sciences (SLS) Stock Down 25% Today? (InvestorPlace)
Jan-03-24 08:05PM	SELLAS Life Sciences Announces Proposed Public Offering (GlobeNewswire)
07:30AM	SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-27-23 08:55AM	SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma (GlobeNewswire)
Dec-21-23 08:15AM	SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas (GlobeNewswire) -5.74%
Dec-14-23 08:30AM	SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia (GlobeNewswire) +14.15%
Dec-13-23 08:30AM	SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET (GlobeNewswire)
Dec-04-23 08:47AM	SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire)
Nov-29-23 08:45AM	SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire)
Nov-13-23 08:50AM	SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS) (GlobeNewswire)
Nov-09-23 04:04PM	SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:57AM	SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting (GlobeNewswire)
Oct-31-23 08:05AM	SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -16.37%
Oct-30-23 09:03AM	SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas (GlobeNewswire) +23.98%
Oct-17-23 08:45AM	SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting (GlobeNewswire) -7.87%
Oct-16-23 08:45AM	SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia (GlobeNewswire)
Oct-12-23 04:05PM	SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia (GlobeNewswire) -10.42% +20.93%
Oct-11-23 08:30AM	SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas (GlobeNewswire) -15.49%
Oct-10-23 04:15PM	SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia (GlobeNewswire)
07:00AM	GenFleet Starts Phase Ib/II Trial of GFH009 (Highly Selective CDK9 Inhibitor) Treating Patients with Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL) (PR Newswire)
Sep-21-23 08:30AM	SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met (GlobeNewswire) +6.67%
Sep-18-23 04:19PM	SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) -6.83%
Aug-22-23 08:30AM	SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications (GlobeNewswire)
Aug-10-23 04:08PM	SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-15-23 09:25AM	Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely (Simply Wall St.)
Jun-28-23 04:00PM	Survival Rates Improve with SELLAS's New Treatment for Severe Lung Cancer, Phase 1 Study Shows (Benzinga)
08:30AM	SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma (GlobeNewswire)
Jun-22-23 08:45AM	SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia (GlobeNewswire)
Jun-15-23 04:05PM	SELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting (GlobeNewswire)
Jun-13-23 08:30AM	SELLAS to Participate in Maxim Group Healthcare Virtual Conference (GlobeNewswire)
May-25-23 05:05PM	SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting (GlobeNewswire) +7.01%
May-16-23 08:30AM	SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia (GlobeNewswire)
May-11-23 04:12PM	SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire) -11.11%
May-04-23 08:30AM	SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study (GlobeNewswire)
Apr-26-23 04:01PM	SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting (GlobeNewswire) +5.04%
Apr-20-23 08:30AM	SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia (GlobeNewswire) -5.77%
Apr-18-23 08:30AM	SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned (GlobeNewswire)
Mar-16-23 04:11PM	SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-23 08:30AM	SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal (GlobeNewswire)
Feb-24-23 08:42AM	Sellas Life Sciences raises $20 million from public offering of stock, warrants (MarketWatch) -53.66%
08:30AM	SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering (GlobeNewswire)
07:29AM	Sellas Lift Sciences stock plunges to pace premarket decliners after stock, warrants offering (MarketWatch)
Feb-23-23 04:01PM	SELLAS Life Sciences Announces Proposed Underwritten Public Offering (GlobeNewswire)
Feb-05-23 07:57AM	Here's Why We're A Bit Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Situation (Simply Wall St.)
Jan-19-23 08:30AM	SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program (GlobeNewswire)
Jan-05-23 08:30AM	SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs (GlobeNewswire)
Dec-13-22 02:49PM	SELLAS Life Sciences Highlights Data From Early Study In Blood Cancer Patients (Benzinga)
08:30AM	SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies (GlobeNewswire)
Dec-08-22 08:30AM	SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned (GlobeNewswire)
Dec-06-22 08:30AM	SELLAS Life Sciences CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute (GlobeNewswire)

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLS

SELLAS Life Sciences Group Inc

Upgrade your FINVIZ experience